BDBarbara Depczynski

Barbara Depczynski

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Barbara Depczynski has a total of 33 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Author reply

    by Barbara Depczynski, Malgorzata Monika Brzozowska, Sue Mei Lau

  • Open Access

    Temporal trends in glycaemia and hospital outcomes in three metropolitan Australian hospitals, 2017–2024

    by Barbara Depczynski, Malgorzata Monika Brzozowska, Sue Mei Lau

    Background: Longitudinal data on in‐hospital glycaemia from Australian hospitals are limited. Aims: The aim of this study was to evaluate the efficacy and safety of current inpatient management strategies in New South Wales hospitals and to compare hospital‐acquired complication (HAC) rates in patients with and without diabetes. We also evaluated trends in diabetes admissions, glycaemia and HAC between 2017 and 2024. Methods: This was a retrospective, observational study of adult medical and surgical admissions to three hospitals over an 8‐year period. Results: Diabetes was observed in 21% of admissions ( n = 84 864/398 803), with the proportion increasing over time (OR 1.008 per year (95% CI 1.005, 1.011), P < 0.001). Among diabetes admissions, the mean blood glucose (BG) of the hospital admission was 9.17 ± 2.82 mmol/L. The odds of BG P < 0.001) or of BG >15 mmol/L (OR 0.999 per quarter (CI 0.998, 0.999), P = 0.012) during the admission decreased over time. The odds of hospital‐acquired infection (HAI) (OR 0.977 per year (95% CI 0.962, 0.992), P < 0.001) and hospital‐acquired cardiac complication (OR 0.973 per year (95% CI 0.947, 0.999), P < 0.039) decreased over time. However, the age‐standardised HAI rate ratio increased in diabetes compared with non‐diabetes admissions (Exp(B) 1.028 per year (95% CI 1.004, 1.032), P = 0.020). The composite HAC rate decreased in non‐diabetes admissions (OR 0.982 per year (95% CI 0.975, 0.989), P < 0.001) but increased in diabetes admissions (OR 1.020 (95% CI 1.009, 1.032), P < 0.001). Conclusion: We demonstrate marginal improvements in glycaemia. While some HACs improved, the gains were of greater magnitude in those without diabetes. These findings highlight both progress and persisting inequities in hospital outcomes for people with diabetes.


  • Open Access

    Retrospective observational study of the association of peak blood glucose during the second 24 hours of admission with hospital-acquired complications in non-critical care admissions to a tertiary referral teaching hospital

    by Barbara Depczynski, Getiye Dejenu Kibret, Andrew Georgiou, Sue Mei Lau

    Introduction Stress hyperglycaemia at hospital presentation is associated with poorer outcomes. Less is known about the risk of poorer outcomes according to achieved glycaemia early in the admission. Research design/methods This was a retrospective observational study of patients admitted to non-critical care wards. The aim was to determine the relationship between the day 2 peak blood glucose and the occurrence of hospital-acquired complications (HACs) or in-hospital mortality. A Cox proportional hazards model, adjusted for relevant covariates, was used to evaluate the impact of day 2 peak glucose on HACs and in-hospital mortality, and we identified peak glucose thresholds correlating with an increase in risk. Results For the whole cohort, day 2 peak glucose was associated with an increased risk of any HAC, aHR=1.06, 95% CI: 1.04, 1.07; but not in-hospital mortality, aHR=0.98, 95% CI: 0.94, 1.01. The risk of HAC infection increased by 4.6% for every mmol/L rise in day 2 peak glucose (aHR=1.05, 95% CI: 1.02, 1.08) in the diabetes cohort compared with 5.5% (aHR=1.06, 95% CI: 1.00, 1.11) in the non-diabetes cohort. The risk of HAC cardiac in the diabetes cohort increased by 5.3% (aHR=1.05, CI: 1.01, 1.10) per mmol/L increase in day 2 peak glucose; no association was found in the non-diabetes cohort (aHR=1.03, 95% CI: 0.94, 1.13). The risk for in-hospital mortality was associated with day 2 peak glucose, aHR=1.11, 95% CI: 1.03, 1.20, in patients without diabetes, but not in patients with diabetes, aHR=1.00, 95% CI: 0.95, 1.06. There was an increase in the risk of HAC once day 2 peak blood glucose exceeded 19.0 mmol/L (whole cohort), with thresholds of 13.6 mmol/L in the non-diabetes group and 19.5 mmol/L in the diabetes group. Conclusion The peak glucose on day 2 was a predictor of HAC in the entire cohort and in-hospital mortality in patients without diabetes.


  • Glucose levels at hospital admission are associated with 5 year mortality

    by N. Wah Cheung, Patrick McElduff, Greg Fulcher, Sandy Middleton, Roger Chen, Barbara Depczynski, Jeff Flack, Jen Kinsella, Margaret Layton, Mark McLean, et al.


  • Open Access

    Association between continued metformin use during hospital admission and hospital‐acquired complications

    by Barbara Depczynski, Abbish Kamalakkannan, Bence Siklosi, Sue Mei Lau

    Aims: The safety of continuing metformin during a hospital admission has not been robustly demonstrated. We evaluated the association of continuing metformin in hospital with the risk for a hospital‐acquired complication (HAC).Methods: This is a retrospective observational study of patients admitted to a medical or surgical ward. We considered those with diabetes who continued metformin (DM/MET group), those who discontinued metformin upon admission (DM/MET‐STOP), and those with diabetes not on metformin just prior to and during admission (DM/NoMET). We prepared propensity score‐matched (PSM) control groups from admitted patients without diabetes. The likelihood of a HAC was determined using a Kaplan–Meier survival analysis. A Cox proportional hazards model was employed to calculate the hazard ratio, adjusted for covariates.Results: Of the 4446 (14%) patients with diabetes, 3331 (10%) were prescribed metformin on admission, and it was continued in 2557 patients. HAC occurred in 5.5% of DM/MET group and 6.4% of the PSM control group. Continuation of metformin was associated with a lower likelihood of HAC, adjusted hazard ratio 0.85 (95% CI 0.69, 1.04), p = 0.117 compared to a PSM‐matched control group without diabetes. The DM/NoMET and DM/MET‐STOP groups had an increased risk for HAC, adjusted HR 1.77 (1.44, 2.18), p < 0.001 and 2.57 (2.10, 3.13), p < 0.001, as compared to their respective PSM control groups.Conclusion: An individualized assessment to continue metformin during hospital admission was associated with a reduced likelihood of HAC, with the caveat that there was limited matching to non‐diabetes controls. This finding warrants further exploration.


  • Nonfunctional Adrenal Adenomas and Increased Risk of Mortality

    by Barbara Depczynski, Myron Lee, Andrea R. Horvath

    To the Editor We read with interest the retrospective case-control study by Patrova et al,1 who demonstrated that nonfunctional adrenal adenoma (NFAA) was associated with an increased overall mortality and mortality owing to cardiovascular disease and cancer. With the lack of data on adrenal hormone measurements, the authors speculated that the development of even slightly elevated cortisol may result in increased cardiovascular disease. The methods carefully excluded confounding by indication; however, other than abnormal expression of growth-related genes, a robust biologically plausible reason for the increased cancer deaths reported is not proposed.

  • Open Access

    Acceptance and Effect of Continuous Glucose Monitoring on Discharge From Hospital in Patients With Type 2 Diabetes: Open-label, Prospective, Controlled Study

    by Barbara Depczynski, Ann Poynten

    Background: Continuous glucose monitors (CGM) can provide detailed information on glucose excursions. There is little information on safe transitioning from hospital back to the community for patients who have had diabetes therapies adjusted in hospital and it is unclear whether newer technologies may facilitate this process. Objective: Our aim was to determine whether offering CGM on discharge would be acceptable and if CGM initiated on hospital discharge in people with type 2 diabetes (T2DM) would reduce hospital re-presentations at 1 month. Methods: This was an open-label study. Adult inpatients with T2DM, who were to be discharged home and required postdischarge glycemic stabilization, were offered usual care consisting of clinic review at 2 weeks and at 3 months. In addition to usual care, participants in the intervention arm were provided with a Libre flash glucose monitoring system (Abbott Australia). An initial run-in phase for the first 20 participants was planned, where all consenting participants were enrolled in an active arm. Subsequently, all participants were to be randomized to the active arm or usual care control group. Results: Of 237 patients screened during their hospital admission, 34 had comorbidities affecting cognition that prevented informed consent and affected their ability to learn to use the CGM device. In addition, 21 were not able to be approached as the material was only in English. Of 101 potential participants who fulfilled eligibility criteria, 19 provided consent and were enrolled. Of the 82 patients who declined to participate, 31 advised that the learning of a new task toward discharge was overwhelming or too stressful and 26 were not interested, with no other details. Due to poor recruitment, the study was terminated without entering the randomization phase to determine whether CGM could reduce readmission rate. Conclusions: These results suggest successful and equitable implementation of telemedicine programs requires that any human factors such as language, cognition, and possible disengagement be addressed. Recovery from acute illness may not be the ideal time for introduction of newer technologies or may require more novel implementation frameworks.


  • Open Access

    Acceptance and Effect of Continuous Glucose Monitoring on Discharge From Hospital in Patients With Type 2 Diabetes: Open-label, Prospective, Controlled Study (Preprint)

    by Barbara Depczynski, Ann Poynten

    BACKGROUND Continuous glucose monitors (CGM) can provide detailed information on glucose excursions. There is little information on safe transitioning from hospital back to the community for patients who have had diabetes therapies adjusted in hospital and it is unclear whether newer technologies may facilitate this process. OBJECTIVE Our aim was to determine whether offering CGM on discharge would be acceptable and if CGM initiated on hospital discharge in people with type 2 diabetes (T2DM) would reduce hospital re-presentations at 1 month. METHODS This was an open-label study. Adult inpatients with T2DM, who were to be discharged home and required postdischarge glycemic stabilization, were offered usual care consisting of clinic review at 2 weeks and at 3 months. In addition to usual care, participants in the intervention arm were provided with a Libre flash glucose monitoring system (Abbott Australia). An initial run-in phase for the first 20 participants was planned, where all consenting participants were enrolled in an active arm. Subsequently, all participants were to be randomized to the active arm or usual care control group. RESULTS Of 237 patients screened during their hospital admission, 34 had comorbidities affecting cognition that prevented informed consent and affected their ability to learn to use the CGM device. In addition, 21 were not able to be approached as the material was only in English. Of 101 potential participants who fulfilled eligibility criteria, 19 provided consent and were enrolled. Of the 82 patients who declined to participate, 31 advised that the learning of a new task toward discharge was overwhelming or too stressful and 26 were not interested, with no other details. Due to poor recruitment, the study was terminated without entering the randomization phase to determine whether CGM could reduce readmission rate. CONCLUSIONS These results suggest successful and equitable implementation of telemedicine programs requires that any human factors such as language, cognition, and possible disengagement be addressed. Recovery from acute illness may not be the ideal time for introduction of newer technologies or may require more novel implementation frameworks.

  • The relationship between admission glucose and lactate with critical illness amongst adult patients presenting to the emergency department

    by Marjy Grealish, Angela L. Chiew, Wayne Varndell, Barbara Depczynski

    Aim Our aim was to determine the relationship between glucose and lactate amongst adult patients admitted to hospital via the emergency department. Method We performed a cross-sectional observational study of 2541 patients admitted via the emergency department who had an admission glucose and lactate measurement available. Results 23% of the whole cohort had a diagnosis of diabetes. Glucose and lactate were predictors of the primary outcome of critical illness defined as composite of intensive care unit (ICU) admission or in-hospital death. In the multivariable analysis, lactate but not glucose remained an independent predictor of ICU/in hospital death in the group without diabetes. In the diabetes group, both glucose and lactate remained independent predictors of ICU admission/ in-hospital death. Conclusions Hyperglycaemia and hyperlactataemia are part of the metabolic response to critical illness. Lactate and a diagnosis of diabetes modify the relationship between glycaemia and critical illness.


  • Association of glycaemic variables with trabecular bone score in post‐menopausal women with type 2 diabetes mellitus

    by B. Depczynski, P. Y. Liew, C. White

    Aim: To determine the relationship between bone microarchitecture, as measured by trabecular bone score, and advanced glycation end‐product accumulation, as assessed by skin autofluorescence.Methods: This was a cross‐sectional study. Participants were 64 post‐menopausal women with type 2 diabetes and 175 post‐menopausal women without diabetes. Trabecular bone score and skin autofluorescence data were obtained at time of bone density measurement.Results: Trabecular bone score and skin autofluorescence were inversely correlated in women with type 2 diabetes (r = –0.34, P = 0.006); no correlation was seen in post‐menopausal women without diabetes (r = –0.029, P = 0.707). After adjustment, neither skin autofluorescence nor a diagnosis of diabetes were associated with trabecular bone score, but HbA1c and waist circumference were independently associated with trabecular bone score.Conclusion: Skin autofluorescence did not predict trabecular bone score. In contrast, glycaemia, as reflected by HbA1c, and visceral adiposity, as reflected by waist circumference, were independently associated with trabecular bone score.